Ajanta Pharma gains on receiving USFDA approval for Almotriptan Malate tablets

08 Mar 2016 Evaluate

Ajanta Pharma is currently trading at Rs. 1434.25, up by 37.05 points or 2.65% from its previous closing of Rs. 1397.20 on the BSE.

The scrip opened at Rs. 1421.00 and has touched a high and low of Rs. 1448.80 and Rs. 1420.00 respectively. So far 4,495 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1720.00 on 12-Aug-2015 and a 52 week low of Rs. 1090.00 on 23-Mar-2015.

Last one week high and low of the scrip stood at Rs. 1448.80 and Rs. 1274.00 respectively. The current market cap of the company is Rs. 12,680.00 crore.

The promoters holding in the company stood at 73.78% while Institutions and Non-Institutions held 10.76% and 15.46% respectively.

Ajanta Pharma has received final approval of Almotriptan Malate Tablets (6.25 mg a 12.5 mg), a generic version of Axert for the treatment of acute migraine pain relief, from the US Food and Drug Administration (FDA). Ajanta Pharma USA Inc., a wholly owned subsidiary of the company, is scheduled to launch Almotriptan Tablets in US shortly.

Almotriptan Tablets is part of an ever-growing portfolio that the company has developed for the US market. To date, FDA has granted the company eight ANDA final approvals and two tentative approvals. An additional 16 ANDAs are under review with FDA.

Ajanta Pharma is a fully-integrated pharmaceutical company with global headquarters in Mumbai, India. Over 6,000 employees are engaged in developing, manufacturing and marketing of quality finished dosages across 35 countries. 


Ajanta Pharma Share Price

2638.75 12.50 (0.48%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×